RT Journal Article
SR Electronic
T1 Hemodynamic modeling of aspirin effects on BOLD responses at 7T
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.30.20019729
DO 10.1101/2020.01.30.20019729
A1 Cao-Tri Do
A1 Zina-Mary Manjaly
A1 Jakob Heinzle
A1 Dario Schöbi
A1 Lars Kasper
A1 Klaas P. Pruessmann
A1 Klaas Enno Stephan
A1 Stefan Frässle
YR 2020
UL http://medrxiv.org/content/early/2020/02/03/2020.01.30.20019729.abstract
AB Aspirin is considered a potential confound for functional magnetic resonance imaging (fMRI) studies. This is because aspirin affects the synthesis of prostaglandin, a vasoactive mediator centrally involved in neurovascular coupling, a process that underlies the blood oxygenated level dependent (BOLD) response. Aspirin-induced changes in BOLD signal are a potential confound for fMRI studies of patients (e.g. with cardiovascular conditions or stroke) who receive low-dose aspirin prophylactically and are compared to healthy controls that do not take aspirin. To examine the severity of this potential confound, we combined high field (7 Tesla) MRI during a simple hand movement task with a biophysically informed hemodynamic model. Comparing elderly volunteers with vs. without aspirin medication, we tested for putative effects of low-dose chronic aspirin on the BOLD response. Specifically, we fitted hemodynamic models to BOLD signal time courses from 14 regions of the human motor system and examined whether model parameter estimates were significantly altered by aspirin. While our analyses indicate that hemodynamics differed across regions, consistent with the known regional variability of the BOLD response, we neither found a significant main effect of aspirin (i.e., an average effect across brain regions) nor an expected drug×region interaction. While our sample size is not sufficiently large to rule out small-to-medium global effects of aspirin, we had adequate statistical power for detecting the expected interaction. Altogether, our analysis suggests that low-dose aspirin, as used for prophylactic purposes, does not strongly affect BOLD signals and may not represent a critical confound for fMRI studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the René and Susanne Braginsky Foundation (KES) and the University of Zurich (KES) as well as by the ETH Zurich Postdoctoral Fellowship Program (SF), the Marie Curie Actions for People COFUND Program (SF), and the University of Zurich Forschungskredit Postdoc (SF).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon acceptance of this paper, the code used for the analysis as well as the BOLD signal time series data will be made publicly available. Furthermore, the code has been cross-checked internally for reproducibility. All analysis streams were performed on the Euler cluster at ETH Zurich. More information on the computational power can be found at https://scicomp.ethz.ch/wiki/Euler.